Immediate Impact
1 from Science/Nature 56 standout
Citing Papers
Targeting ROS in cancer: rationale and strategies
2024 Standout
Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders
2024 Standout
Works of Ágnes Ruzsa being referenced
Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
2014
Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
2011
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Ágnes Ruzsa | 115 | 165 | 47 | 117 | 9 | 296 | |
| Bambang Hermani | 63 | 126 | 60 | 116 | 11 | 286 | |
| Sarah Schimansky | 95 | 70 | 50 | 94 | 17 | 302 | |
| Guy Monceaux | 70 | 170 | 105 | 174 | 7 | 330 | |
| Annie Ellis | 66 | 179 | 39 | 41 | 12 | 316 | |
| Edvard Abel | 112 | 102 | 73 | 122 | 12 | 226 | |
| Laura Hargreaves | 184 | 191 | 66 | 170 | 9 | 327 | |
| Gert Henriksson | 76 | 115 | 170 | 76 | 13 | 324 | |
| Rachel Liang | 61 | 80 | 16 | 29 | 16 | 315 | |
| V. Barley | 79 | 58 | 51 | 34 | 14 | 242 | |
| Jose Bonilla | 67 | 79 | 65 | 22 | 17 | 291 |
All Works
Loading papers...